V1RH2 Inhibitors
V1RH2 inhibitors are a class of chemical compounds specifically targeting the V1RH2 protein, which is a part of the vacuolar-type H+-ATPase (V-ATPase) complex. The V-ATPase complex is crucial for acidifying various intracellular compartments such as lysosomes, endosomes, and vacuoles by using energy from ATP hydrolysis to pump protons across membranes. The V1RH2 protein is located in the V1 domain of this complex and is involved in the ATP hydrolysis process that drives the proton pump mechanism. Inhibitors of V1RH2 are designed to interact with this protein and disrupt its function, thereby impacting the overall activity of the V-ATPase.
The mechanism of action of V1RH2 inhibitors involves binding to the V1RH2 protein, which can interfere with the protein's ability to participate in ATP hydrolysis. By doing so, these inhibitors can affect the assembly and stability of the V1 domain of the V-ATPase complex. This disruption hinders the enzyme's function in proton transport and intracellular compartment acidification. The impact of these inhibitors on V1RH2 provides valuable insights into the role of this protein within the V-ATPase complex, shedding light on the broader implications of V-ATPase activity in cellular functions such as pH regulation and vesicular trafficking. Through their specific interaction with V1RH2, these compounds offer a way to explore and understand the functional contributions of V1RH2 to the V-ATPase machinery.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA), leading to intracellular calcium depletion, which may downregulate V1R189 expression. | ||||||
Cyclopiazonic Acid | 18172-33-3 | sc-201510 sc-201510A | 10 mg 50 mg | $176.00 $624.00 | 3 | |
Cyclopiazonic acid inhibits SERCA, leading to intracellular calcium depletion, which may downregulate V1R189 expression. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine inhibits L-type calcium channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
Ruthenium red | 11103-72-3 | sc-202328 sc-202328A | 500 mg 1 g | $188.00 $250.00 | 13 | |
Ruthenium Red is a calcium channel blocker that inhibits calcium influx, potentially interfering with the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
SK&F 96365 | 130495-35-1 | sc-201475 sc-201475B sc-201475A sc-201475C | 5 mg 10 mg 25 mg 50 mg | $103.00 $158.00 $397.00 $656.00 | 2 | |
SKF-96365 inhibits store-operated calcium entry (SOCE), potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
Gadolinium(III) chloride | 10138-52-0 | sc-224004 sc-224004A | 5 g 25 g | $153.00 $357.00 | 4 | |
Gadolinium chloride inhibits non-selective cation channels, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits calcium release from the sarcoplasmic reticulum, potentially reducing intracellular calcium levels and inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
EGTA | 67-42-5 | sc-3593 sc-3593A sc-3593B sc-3593C sc-3593D | 1 g 10 g 100 g 250 g 1 kg | $21.00 $65.00 $120.00 $251.00 $815.00 | 23 | |
EGTA is a calcium chelator that reduces intracellular calcium levels, potentially inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a calcium chelator that reduces intracellular calcium levels, potentially inhibiting the calcium-dependent signaling pathways involved in V1R189 expression. | ||||||